SIRPA and neoplasm: Disruption of the CD47-SIRPα axis by monoclonal antibodies results in enhanced phagocytosis of both solid and hematopoietic tumor cells, including increased phagocytosis of GBM cells in vitro and significant anti-tumor activity in vivo [19, 23].